Last edition
News about Global Pharma
Vanda and Anaptys to Develop and Commercialize Imsidolimab
GPP is a rare skin disorder often caused by mutations in the IL36RN gene that codes for a regulatory protein that balances the activity of the proinflammatory IL-36 family of cytokines.
Global Pharma | 04/02/2025 | By Aishwarya | 556
Moberg Pharma AB and Allderma Announce Launch of Terclara in Norway
Moberg Pharma AB and Allderma have announced the launch of Terclara (MOB-015) in Norway, following its success in Sweden, with initial pharmacy deliveries expected in February 2025.
Global Pharma | 03/02/2025 | By Manvi | 536
Alterity Therapeutics has raised approximately AUD 2.13 million in the US via its at-the-market (ATM) facility and expects to receive around AUD 5.69 million in rebates from the Australian Taxation Office, enabling the acceleration of clinical and business development activities for its lead asset, ATH434.
Global Pharma | 03/02/2025 | By Manvi | 109
Clinigen Announces Collaboration with Tepsivo
At the heart of Tepsivo’s offering is its cutting-edge PV platform and proprietary automated PV software powered by artificial intelligence and other digital innovations.
Global Pharma | 03/02/2025 | By Aishwarya | 249
Cognizant Extends Alliance with Gilead to Boost Advanced Technology Applications
Gilead is expected to enhance its efficiency through leveraging Cognizant's expertise in AI and advanced technology applications.
Global Pharma | 03/02/2025 | By Aishwarya | 411
Union Budget 2025 to Ease Drug Costs with More Medicines Under Assistance Schemes
The Union Budget also expands the list of medicines that will be exempt from Basic Customs Duty under pharmaceutical companies’ Patient Assistance Programmes.
Global Pharma | 01/02/2025 | By Aishwarya | 1104
Kadimastem Shareholders Approve Merger with NLS Pharmaceutics
The merger brings NLS and Kadimastem one step closer to creating a combined Nasdaq-traded biotechnology company with a robust portfolio of advanced therapies for neurodegenerative diseases and diabetes.
Global Pharma | 01/02/2025 | By Abha | 277
OneSource Achieves INR 3,926 Million Revenue in Q3FY25
OneSource demonstrated exceptional profitability with EBITDA reaching INR 1,432 million, an 85 percent increase compared to the previous quarter, resulting in a robust EBITDA margin of 36.5 percent, up by 1,334 basis points quarter-on-quarter.
Global Pharma | 01/02/2025 | By Aishwarya | 813
US FDA Approves New Non-Opioid Treatment for Moderate to Severe Acute Pain
The US FDA has approved Journavx (suzetrigine), a first-in-class non-opioid analgesic, for treating moderate to severe acute pain in adults, marking a significant milestone in pain management alternatives.
Global Pharma | 31/01/2025 | By Manvi | 149
UK Biocentre Picks Azenta's BioArc Ultra Automated Storage System to Power Research Excellence
UK Biocentre will utilize the new BioArc Ultra™ to deliver on critical research projects including the United Kingdom’s largest health research program – Our Future Health.
Global Pharma | 31/01/2025 | By Aishwarya | 201
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy